Test Menu
Test Change Details
Allergy & Immunology
Cardiology & Coagulation
Infectious Disease
Women's Health
92062: Diabetes And Ascvd Risk Panel With Scores Print View
Glucose     mg/dL 
Hemoglobin A1c      
Cholesterol, Total     mg/dL 
HDL Cholesterol     mg/dL 
Triglycerides     mg/dL 
LDL Chol, Calculated CALC    mg/dL 
Cholesterol/HDL Ratio CALC    calc 
Non-HDL Cholesterol CALC    mg/dL (calc) 
8 Year Diabetes Risk     % 
10 Year ASCVD Risk     % 
10 Year ASCVD Risk Goal     % 
Lifetime ASCVD Risk     % 
Height Feet     ft 
Height Inches     in 
Weight     lbs 
Calculated BMI      
African American      
Systolic Blood Pressure     mmHg 
Diastolic Blood Pressure     mmHg 
Treatment for High B.P.      
Parental History of Diab      
Current Smoker      

1 Serum Separator Tube 4 (2) mL   Room Temperature - 48 Hour(s)/Refrigerated - 5 Day(s)/Frozen - 28 Day(s)  
2 Whole Blood EDTA 1 (0.5) mL   Room Temperature - 7 Day(s)/Refrigerated - 7 Day(s)/Frozen - 6 Month(s)  

The increasing prevalence of obesity has led to an epidemic of diabetes mellitus and related complications, including ASCVD. Prediction of the risk of ASCVD and of developing diabetes in the lab report will simplify and improve the communication of those risks to patients. This panel provides the 10-year and lifetime risk of ASCVD events and the 8-year risk of developing diabetes. The lipid panel results will aid in the assessment of ASCVD. Assessment of 10-year risk of a first atherosclerotic cardiovascular (ASCVD) event is recommended by the 2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. These guidelines recommend initiating statin therapy based on 10-year ASCVD risk score. Assessment of 8-year risk of developing diabetes mellitus is based on laboratory test results with anthropomorphic data and family history. This algorithm was developed in the Framingham cohort, and is intended to aid in the identification of patients at risk for developing diabetes, permitting pharmacological or lifestyle interventions.

Fasting required. Fasting is defined as no consumption of
food or beverage other than water for at least 8 hours before

For risk calculations to be performed, the following patient-specific
information must be provided at the time of order:
Age: Years
Gender: M (for male) or F (for female)
Height Feet: Feet
Height Inches: Inches
Weight: lbs
Race - African American: Y (for yes) or N (for no)
Systolic Blood Pressure: mmHg
Diastolic Blood Pressure: mmHg
Treatment for High B.P.: Y (for yes) or N (for no)
Diabetes Status: Y (for yest) or N (for no)
Parental History of Diab: Y (for yes) or N (for no)
Smoking Status: Y (for yes) or N (for no)

Patient Preparation

The assay manufacturer Beckman Coulter advises: "N-Acetyl Cysteine
(NAC), when administered in therapeutic concentrations (for the
treatment of acetaminophen overdose), has been determined to
interfere with assays for Cholesterol, Uric Acid where "NAC
interference may lead to falsely low results." According to Beckman
Coulter, the NAC interference should be insignificant by 12 hours
after completion of the initial loading dose of an IV infusion
treatment regimen consisting of an initial loading dose of 150 mg/kg
administered over 1 hr, a second dose of 50 mg/kg administered over 4
hrs and a third dose of 100 mg/kg administered over 16 hrs.
Setup Schedule

Reported (Analytical Time)
3 days

CPT Codes

The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.

Message: Includes: Glucose* Hemoglobin A1c* Cholesterol, Total* HDL Cholesterol* Triglycerides* Non-HDL and Calculated Components* Risks and Personal Factors
Reject Criteria: Gross hemolysis; moderate to gross icterus
Specimen Requirements:
4 mL (2 mL minimum) serum collected in a serum separator tube and 1 mL (0.5 mL minimum) whole blood collected in an EDTA (lavender-top) tube No other acceptable specimens
Transport Temperature: Refrigerated
Methodology: Spectrophotometry, Immunoturbidimetry, Enzymatic

1996 - 2019 Quest Diagnostics Nichols Institute of Valencia
For test information, please call Client Services at 800-421-4449.

San Francisco Web Design & Database